JSE drops on reports of failed Covid-19 treatment, while rand firms
The Financial Times has reported that the antiviral drug, remdesivir, ‘flopped’ in its first clinical trial
24 April 2020 - 13:23
The JSE was weaker on Friday, along with its global counterparts, as doubts about progress in the development of drugs to treat the coronavirus weighed on investor sentiment.
Recently, markets were boosted by reports that Gilead Sciences’ antiviral drug, remdesivir, had helped Covid-19 patients with severe symptoms. However, the Financial Times has reported that the drug “flopped” in its first clinical trial...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.